Guest analysis published on Börsvärlden's webpage regarding Scandinavian ChemoTech

Please read the guest analysis that was published on Börsvärldens web page regarding Scandinavian ChemoTech - see attached document for the fully translated version of the analysis.

Link to the swedish article: Börsvärlden - Gästanalys - Scandinavian ChemoTech

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

info@chemotech.se

 

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe